Bone News and Research

RSS

Exelixis reports positive interim data from cabozantinib phase 2 trial on HCC

Exelixis, Inc. today reported positive updated interim data from the cohort of hepatocellular carcinoma (HCC) patients participating in the ongoing phase 2 randomized discontinuation trial (RDT) of cabozantinib.

4 Jun 2012

Onyx announces data from regorafenib Phase 3 trial on GIST

Onyx Pharmaceuticals today announced data from the Phase 3 GRID (GIST – Regorafenib In Progressive Disease) trial evaluating the investigational drug regorafenib, a Bayer compound, in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease had progressed despite prior treatment with imatinib and sunitinib.

4 Jun 2012

Favorable results from CytRx’s INNO-206 Phase 1b/2 trial on soft tissue sarcomas

CytRx Corporation, a biopharmaceutical company specializing in oncology, announces that favorable clinical results from its Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate INNO-206 in patients with advanced solid tumors, primarily soft tissue sarcomas, are being presented today at the American Society of Clinical Oncology (ASCO) conference in Chicago.

4 Jun 2012

Reumofan Plus may have harmful pharmaceutical ingredients, warns FDA

The U.S. Food and Drug Administration is warning consumers that Reumofan Plus, marketed as a "natural" dietary supplement for pain relief and other serious conditions, contains several active pharmaceutical ingredients not listed on the label that could be harmful.

2 Jun 2012

Clinical trial to examine effectiveness of combined vaccine and hormone treatment for prostate cancer

Investigators at The Cancer Institute of New Jersey (CINJ) have partnered with the National Cancer Institute (NCI) and launched a clinical trial examining the effectiveness of a combined vaccine and hormone treatment for prostate cancer that is resistant to hormone therapy and not visible on imaging tests such as a CT scan and a bone scan.

2 Jun 2012

First study to correlate dietary fiber intake with inflammatory markers in adolescents

Adolescents who don't eat enough fiber tend to have bigger bellies and higher levels of inflammatory factors in their blood, both major risk factors for cardiovascular disease and diabetes, researchers report.

2 Jun 2012

Inhibiting IRE1α-XBP1 pathway impacts survival of myeloma cells

Results published in Blood, the official journal of the American Society of Hematology, confirm that inhibition of the IRE1α-XBP1 pathway impacts the survival of myeloma cells, suggesting a promising therapeutic option in multiple myeloma.

2 Jun 2012

Montefiore experts available to discuss cancer research at 2012 ASCO meeting

Bringing together international experts with the latest technologies and pioneering research, Montefiore Einstein Center for Cancer Care, in collaboration with the National Cancer Institute-designated Albert Einstein Cancer Center, advances the front lines of prevention, diagnosis and treatment of rare and common cancers.

2 Jun 2012

European Multidisciplinary Meeting on Urological Cancers to be held in Barcelona

With the goal to deliver an in-depth review of the latest multi-modal management strategies for urological cancers, the 4th European Multidisciplinary Meeting on Urological Cancers (EMUC) will be held from 16 to 18 November 2012 in Barcelona, Spain.

2 Jun 2012

$Gene variant linked to postmenopausal fracture risk$

Gene variant linked to postmenopausal fracture risk

Women who carry a variation in a gene involved in blocking bone morphogenic proteins are more likely to have fragility fractures than women without the variant, Greek research shows.

1 Jun 2012

Hip arthroplasty pseudotumors ‘cause for great concern’

Pseudotumors may be 10 times more common in patients after metal-on-metal hip resurfacing and total hip replacement than thought, suggest Dutch researchers.

1 Jun 2012

Distinctive protein pathways in certain leukemia patients

Scientists at Rice University and the University of Texas MD Anderson Cancer Center have successfully profiled protein pathways found to be distinctive to leukemia patients with particular variants of the disease.

1 Jun 2012

NYUCD receives NIH grant for ‘Biomarkers of Periodontal Disease Progression’ project

New York University College of Dentistry has been selected as one of five institutions that are sharing a $20.7 million grant from the National Institute of Dental and Craniofacial Research (NIH) to the Forsyth Institute to find new ways to diagnose and fight periodontal disease.

1 Jun 2012

Beta-carotene safe to use during radiation therapy for prostate cancer

Despite past safety concerns, the antioxidant supplement beta-carotene, is safe to use during radiation therapy treatments for prostate cancer and does not increase the risk of prostate cancer death or metastases, according to a study in the May issue of the International Journal of Radiation Oncology•Biology•Physics, the official scientific journal of the American Society for Radiation Oncology.

1 Jun 2012

Scientists succeed in solving first structure of a Wnt protein

The 20 proteins in the Wnt family are some of the most important proteins in controlling how an organism develops and grows, but for 30 years scientists have not known what these vital proteins actually look like. The proteins have eluded standard visualization techniques, in large part because they do not dissolve well in the water-based liquids normally used for biochemical studies.

1 Jun 2012

Velos releases new iPad app for clinicians in oncology, bone marrow transplantation

Velos, Inc. today announced the release of Velos Aversi, an iPad app for clinicians in oncology and bone marrow transplantation. The app is now available for download on the Apple App Store.

1 Jun 2012

Vitamin D3 supplements could provide more health benefits

New research funded by the Biotechnology and Biological Sciences Research Council (BBSRC) has shown that vitamin D3 supplements could provide more benefit than the close relative vitamin D2.

1 Jun 2012

Fall prevention needed in multiple sclerosis patients

Patients with multiple sclerosis are at increased risk for fractures, particularly those related to falls, a study shows.

31 May 2012

$Vertebroplasty feasible for at least 1 year after fracture$

Vertebroplasty feasible for at least 1 year after fracture

Patients with subacute and chronic osteoporotic vertebral compression fractures can be successfully treated with percutaneous vertebroplasty between 2 and 12 months after symptom onset, say researchers.

31 May 2012

CTI announces results from PIX301 phase 3 trial of Pixuvri for NHL

Cell Therapeutics, Inc. today announced that results from its PIX301 phase 3 clinical trial of Pixuvri (pixantrone) have been published online in The Lancet Oncology.

31 May 2012